NPRO Napro Biotherapeutics (MM)

Stephen K. Carter, M.D. Joins NaPro Board of Directors BOULDER, Colo., March 10 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc. announced today the appointment of Stephen K. Carter, M.D. to its Board of Directors effective March 9, 2004. Dr.Carter has over forty years of experience in oncology and pharmaceutical drug development as a practicing clinician, medical researcher, Clinical Professor of Medicine (University of California, San Francisco) and a senior member of the National CancerInstitute (NCI). In addition, Dr. Carter served as a pharmaceutical executive for thirteen years at Bristol-Myers Squibb where he held the position of Senior Vice President, Worldwide Clinical Research and Development. At the National Cancer Institute Dr. Carter held the position of Deputy Director, Division of Cancer Treatment, where, for over a decade, he helped shape the cancer therapy evaluation branch of the NCI. Later, at Bristol- Myers Squibb, Dr. Carter was responsible for the development of a number of cancer chemotherapeutics including both Carboplatin and Taxol. "All of us at NaPro welcome the integrity, broad experience, and judgment that Dr. Carter brings to both our commercial and medical deliberations as we advance our preclinical portfolio of anticancer agents into human clinical trials over the next year," commented Leonard Shaykin, Chairman and Chief Executive Officer of NaPro. "We are honored by Dr. Carter's participation in the Company and look forward to his contributionon the Board." In a related matter, Marc J. Ostro, Ph.D., a Managing Director of T.L. Ventures, has decided to resign from the Board of NaPro BioTherapeutics effective March 11, 2004. About NaPro BioTherapeutics NaPro BioTherapeutics, Inc., is a life science company focused on the development of therapies for the treatment of cancer and hereditary disease. Forward Looking Statements The statements in this news release that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release, based on currently available information. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties including: risks associated with development of anti-cancer agents, including competition from companies in similar businesses, limitations on the ability to market products because of the intellectual property rights of third parties, the ability to obtain, maintain and enforce patents; the costs of continuing development of any or all of the Company's development programs; the timing of when those programs will enter the clinic; the successful commercialization of the Company's platform technologies; the fact that the Company's business will require substantial additional investment that the Company has not secured; and the risk that the Company's cash not be sufficient to fund the Company's strategic plans for the initial development new proprietary therapeutic candidates; and all of those factors identified under the captions "Risk Factors," "Special Note Regarding Forward Looking Statements" or "Cautionary Note Regarding Forward Looking Statements" in the Company's documents filed from time to time with the SEC, including the Company's registration statement on Form S-3, as amended, dated August 8, 2003, its Annual Report on Forms 10-K and 10-K/A for the year ending December 31, 2002 filed with the SEC on March 27, April 30, August 8 and October 24, 2003, and its Quarterly Report on Form 10-Q for the quarter ended October 1, 2003 filed with the Securities and Exchange Commission on November 14, 2003. Should one or more of these risks materialize (or the consequences of such a development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from those forecasted or expected. The Company disclaims any intention or obligation to update publicly or revise such statements whether as a result of new information, future events or otherwise. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro BioTherapeutics, Inc., +1-212-218-8715; or Investors, Lilian Stern of Stern Investor Relations, +1-212-362-1200; or Media, Peter Steinerman, +1-516-374-3031, both for NaPro BioTherapeutics, Inc. Web site: http://www.naprobio.com/

Copyright